At the time of writing, Catalyst Pharmaceuticals Inc [CPRX] stock is trading at $16.62, up 2.59%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The CPRX shares have gain 4.79% over the last week, with a monthly amount glided 21.85%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 13, March 2024, Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD). In a post published today on Yahoo Finance, AGAMREE® (vamorolone) a Novel Alternative Corticosteroid with Demonstrated Properties in Maintaining Efficacy and a Well-Tolerated Side Effect Profile.
From an analyst’s perspective:
Catalyst Pharmaceuticals Inc [NASDAQ: CPRX] stock has seen the most recent analyst activity on March 07, 2024, when BofA Securities initiated its Buy rating and assigned the stock a price target of $23. Previously, Oppenheimer started tracking the stock with Outperform rating on December 21, 2023, and set its price target to $30. On August 24, 2022, downgrade downgraded it’s rating to Neutral and revised its price target to $15.50 on the stock. Cantor Fitzgerald started tracking the stock assigning a Overweight rating. Piper Jaffray upgraded its rating to Overweight for this stock on October 05, 2016. In a note dated April 26, 2016, Piper Jaffray downgraded an Neutral rating on this stock and revised its target price from $6 to $1.
For the past year, the stock price of Catalyst Pharmaceuticals Inc fluctuated between $11.09 and $18.22. Currently, Wall Street analysts expect the stock to reach $19.38 within the next 12 months. Catalyst Pharmaceuticals Inc [NASDAQ: CPRX] shares were valued at $16.62 at the most recent close of the market. An investor can expect a potential return of 16.61% based on the average CPRX price forecast.
Analyzing the CPRX fundamentals
According to Catalyst Pharmaceuticals Inc [NASDAQ:CPRX], the company’s sales were 398.20M for trailing twelve months, which represents an 81.98% jump. Gross Profit Margin for this corporation currently stands at 0.85% with Operating Profit Margin at 0.22%, Pretax Profit Margin comes in at 0.24%, and Net Profit Margin reading is 0.18%. To continue investigating profitability, this company’s Return on Assets is posted at 0.15, Equity is 0.2 and Total Capital is 0.22. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 16.33 points at the first support level, and at 16.04 for the second support level. However, for the 1st resistance point, the stock is sitting at 16.93, and for the 2nd resistance point, it is at 17.24.
Catalyst Pharmaceuticals Inc [CPRX] reported earnings per share of $0.31 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of $0.26/share, meaning a difference of $0.05 and a surprise factor of 19.20%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.29 per share as compared to estimates of -$0.28 per share, a difference of -$0.01 representing a surprise of -3.60%.
Ratios To Look Out For
It is important to note that Catalyst Pharmaceuticals Inc [NASDAQ:CPRX] has a current ratio of 2.88. As well, the Quick Ratio is 2.68, while the Cash Ratio is 1.81. Considering the valuation of this stock, the price to sales ratio is 4.92, the price to book ratio is 4.59 and price to earnings (TTM) ratio is 27.28.
Transactions by insiders
Recent insider trading involved Harper Molly, Director, that happened on Dec 15 ’23 when 14000.0 shares were sold. Director, Tierney David S completed a deal on Dec 12 ’23 to sell 50000.0 shares. Meanwhile, VP, Treasurer and CFO GRANDE ALICIA sold 60000.0 shares on Dec 11 ’23.
